Perceive Biotherapeutics, Inc.
Clinical trials sponsored by Perceive Biotherapeutics, Inc., explained in plain language.
-
New eye injection aims to halt vision loss in dry AMD
Disease control OngoingThis early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision…
Phase 1/2 • Sponsor: Perceive Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Scientists track Long-Term safety of experimental AMD therapy
Knowledge-focused By invitation onlyThis study follows people with advanced dry age-related macular degeneration who previously received a one-time injection of the experimental treatment VOY-101. Researchers are monitoring participants over the long term to check for any side effects related to the treatment. The …
Sponsor: Perceive Biotherapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC